$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on R

Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenn

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dys

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opagan

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and

Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expect

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.13) per share. This is a 181.25 percent de

Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after report

US stocks down, Nasdaq falls 0.4% on Thursday. Jobless claims rise to 214,000. Utilities jump 2.1%,

Dow Jones drops 0.44%, NASDAQ falls 0.31%, S&P 500 down 0.22%. Tesla shares drop 1% after report

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a U.S. specialty pharmaceutical company, today announ

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.01) per share. This is a 50 percent increa

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on develop

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), today announced an important update regarding its Cal

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decre

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori the

Premier Membership includes 4,350 U.S. HospitalsNASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumb

Injectable Ibuprofen Approved for Treating Pain & FeverNASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswi

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.02 per share. This is a 100 percent incre

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic med

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to prot

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ c

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 420 percent incre

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.02) per share. This is a 81.82 percent inc

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne mu

FDA approval streamlines Acetadote dosing, enhancing safety and efficiency in treating acetaminophen

Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lesse

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021539s019lbl.pdf